NCT04016233View on ClinicalTrials.gov

Tenofovir Rectal Douche to Prevent HIV Transmission

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

April 27, 2021

Study Completion Date

April 27, 2021

Conditions
HIV/AIDSHIV Prevention
Interventions
DRUG

Tenofovir douche

660 mg TFV in 125 mL hypo-osmolar solution

Trial Locations (2)

15213

University of Pittsburgh, Pittsburgh

21287

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of Pittsburgh

OTHER

lead

Johns Hopkins University

OTHER

NCT04016233 - Tenofovir Rectal Douche to Prevent HIV Transmission | Biotech Hunter | Biotech Hunter